Ovid Therapeutics Inc

-0.04 (-0.99%)
Earnings Announcements

Ovid Therapeutics Reports Q4 Loss Per Share Of $0.34

Published: 03/15/2021 12:52 GMT
Ovid Therapeutics Inc (OVID) - Ovid Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results, Provides Corporate Update for 2021.
Q4 Loss per Share $0.34.
Q4 Earnings per Share Estimate $-0.31 -- Refinitiv Ibes Data (analyst estimates).
Q4 Revenue $5.7 Million.
Q4 Revenue Estimate $4.2 Million -- Refinitiv Ibes Data (analyst estimates).
As of December 31, 2020, Cash, Cash Equivalents and Short-term Investments Totaled $72.0 Million.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.19

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.19

More details on our Analysts Page.